Michelle Huckaby Lewis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michelle Huckaby Lewis has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Aaron Goldenberg
Department of Bioethics, Case Western Reserve University, Cleveland, Ohio; and
1 shared publication- Aaron J. Goldenberg
Case Western Reserve University School of Medicine Cleveland Ohio USA
1 shared publication - Andrea Sutherland
Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205 USA
1 shared publication - Bob Wong
College of Nursing, University of Utah, Salt Lake City, USA
1 shared publication - Chloe L. Thio
Johns Hopkins University
1 shared publication - Daniel A. Salmon
Department of International Health, Health Behavior and Society, and Institute for Vaccine Safety, Johns Hopkins University Bloomberg School of Public Health
1 shared publication
Latest Publications
- Open Access
- 18 November 2014
- Published by Springer Nature in Genome Medicine
- Vol. 6 (11) , 106
Genomics and infectious disease: a call to identify the ethical, legal and social implications for public health and clinical practice
Advances in genomics are contributing to the development of more effective, personalized approaches to the prevention and treatment of infectious diseases. Genetic sequencing technologies are furthering our understanding of how human and pathogen genomic factors - and their interactions - contribute to individual differences in immunologic responses to vaccines, infections and drug therapies. Such understanding will influence future policies and procedures for infectious disease management. With the potential for tailored interventions for particular individuals, populations or subpopulations, ethical, legal and social implications (ELSIs) may arise for public health and clinical practice. Potential considerations include balancing health-related benefits and harms between individuals and the larger community, minimizing threats to individual privacy and autonomy, and ensuring just distribution of scarce resources. In this Opinion, we consider the potential application of pathogen and host genomic information to particular viral infections that have large-scale public health consequences but differ in ELSI-relevant characteristics such as ease of transmission, chronicity, severity, preventability and treatability. We argue for the importance of anticipating these ELSI issues in advance of new scientific discoveries, and call for the development of strategies for identifying and exploring ethical questions that should be considered as clinical, public health and policy decisions are made.
- 18 November 2014
- Published by Springer Nature in Genome Medicine
- Vol. 6 (11) , 106
Open AccessGenomics and infectious disease: a call to identify the ethical, legal and social implications for public health and clinical practice
Advances in genomics are contributing to the development of more effective, personalized approaches to the prevention and treatment of infectious diseases. Genetic sequencing technologies are furthering our understanding of how human and pathogen genomic factors - and their interactions - contribute to individual differences in immunologic responses to vaccines, infections and drug therapies. Such understanding will influence future policies and procedures for infectious disease management. With the potential for tailored interventions for particular individuals, populations or subpopulations, ethical, legal and social implications (ELSIs) may arise for public health and clinical practice. Potential considerations include balancing health-related benefits and harms between individuals and the larger community, minimizing threats to individual privacy and autonomy, and ensuring just distribution of scarce resources. In this Opinion, we consider the potential application of pathogen and host genomic information to particular viral infections that have large-scale public health consequences but differ in ELSI-relevant characteristics such as ease of transmission, chronicity, severity, preventability and treatability. We argue for the importance of anticipating these ELSI issues in advance of new scientific discoveries, and call for the development of strategies for identifying and exploring ethical questions that should be considered as clinical, public health and policy decisions are made.
- 1 April 2012
- Published by Elsevier in Social Science & Medicine
- Vol. 74 (8) , 1305-1309
Assessing public attitudes on the retention and use of residual newborn screening blood samples: A focus group study
- 1 April 2012
- Published by Elsevier in Social Science & Medicine
- Vol. 74 (8) , 1305-1309
Assessing public attitudes on the retention and use of residual newborn screening blood samples: A focus group study
- 1 April 2011
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 127 (4) , 703-712
State Laws Regarding the Retention and Use of Residual Newborn Screening Blood Samples
BACKGROUND: After newborn screening has been completed, many states retain residual newborn screening dried blood samples for various purposes, including program evaluation, quality assurance, and biomedical research. The extent to which states possess legal authority to retain residual dried blood samples (DBS) and use them for purposes unrelated to newborn screening is unclear. OBJECTIVE: The purpose of this study was to evaluate state laws regarding the retention and use of DBS. METHODS: State statutes and regulations related to newborn screening of all 50 states plus the District of Columbia were accessed online between November 2008 and December 2009 and reviewed by 2 independent reviewers to determine the extent to which the retention and use of DBS were addressed. RESULTS: The retention or use of DBS has not been addressed in 18 states. In 4 states, DBS becomes state property. Eight states require that parents be provided information regarding the retention of DBS. Parents in 5 states may request the destruction of their child's residual sample. Parental consent is required under certain circumstances to release DBS for research in 6 states. One state prohibits DBS from being used for research purposes. CONCLUSIONS: States have wide variability in their policies regarding the retention and use of DBS. Many states have not addressed key issues, and some states that retain DBS may be acting outside the scope of their legal authority. The lack of transparency on the part of states in retaining DBS may undermine public trust in state newborn screening programs and the research enterprise.
- 1 April 2011
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 127 (4) , 703-712
State Laws Regarding the Retention and Use of Residual Newborn Screening Blood Samples
BACKGROUND: After newborn screening has been completed, many states retain residual newborn screening dried blood samples for various purposes, including program evaluation, quality assurance, and biomedical research. The extent to which states possess legal authority to retain residual dried blood samples (DBS) and use them for purposes unrelated to newborn screening is unclear. OBJECTIVE: The purpose of this study was to evaluate state laws regarding the retention and use of DBS. METHODS: State statutes and regulations related to newborn screening of all 50 states plus the District of Columbia were accessed online between November 2008 and December 2009 and reviewed by 2 independent reviewers to determine the extent to which the retention and use of DBS were addressed. RESULTS: The retention or use of DBS has not been addressed in 18 states. In 4 states, DBS becomes state property. Eight states require that parents be provided information regarding the retention of DBS. Parents in 5 states may request the destruction of their child's residual sample. Parental consent is required under certain circumstances to release DBS for research in 6 states. One state prohibits DBS from being used for research purposes. CONCLUSIONS: States have wide variability in their policies regarding the retention and use of DBS. Many states have not addressed key issues, and some states that retain DBS may be acting outside the scope of their legal authority. The lack of transparency on the part of states in retaining DBS may undermine public trust in state newborn screening programs and the research enterprise.
- 20 June 2007
- Published by American Medical Association (AMA) in JAMA
- Vol. 297 (23) , 2633-2637
The Locality Rule and the Physician's Dilemma
The purpose of medical malpractice law is to protect patients from substandard medical care and to compensate them for injuries sustained as a result of substan
- 20 June 2007
- Published by American Medical Association (AMA) in JAMA
- Vol. 297 (23) , 2633-2637
The Locality Rule and the Physician's Dilemma
The purpose of medical malpractice law is to protect patients from substandard medical care and to compensate them for injuries sustained as a result of substan